{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:40:09Z","timestamp":1785883209615,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272415"],"award-info":[{"award-number":["82272415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871728"],"award-info":[{"award-number":["81871728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472369"],"award-info":[{"award-number":["82472369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022YQ045"],"award-info":[{"award-number":["2022YQ045"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2019CXJQ03"],"award-info":[{"award-number":["2019CXJQ03"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cca.2025.120817","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:23:44Z","timestamp":1767425024000},"page":"120817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Quantification of plasma mutant calreticulin for diagnosis and therapeutic response assessment of peginterferon-\u03b1 in myeloproliferative neoplasms: A proof-of-concept study"],"prefix":"10.1016","volume":"582","author":[{"given":"Jingjing","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gusheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cca.2025.120817_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-020-0290-9","article-title":"The new WHO classification for essential thrombocythemia calls for revision of available evidences","volume":"10","author":"Barbui","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2025.120817_bb0010","series-title":"The 5th edition Of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms, Leukemia","first-page":"1703","volume":"36","author":"Khoury","year":"2022"},{"issue":"11","key":"10.1016\/j.cca.2025.120817_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.cca.2025.120817_bb0020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.21360","article-title":"Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy","volume":"84","author":"Palandri","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.cca.2025.120817_bb0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.2023023428","article-title":"CALR mutation burden in essential thrombocythemia and disease outcome","volume":"143","author":"Guglielmelli","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120817_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-023-00786-x","article-title":"Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis","volume":"13","author":"Guglielmelli","year":"2023","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.cca.2025.120817_bb0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2025.120817_bb0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.cca.2025.120817_bb0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2025.120817_bb0055","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1002\/ajh.25065","article-title":"Mayo CALR mutation type classification guide using alpha helix propensity","volume":"93","author":"Lasho","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"25","key":"10.1016\/j.cca.2025.120817_bb0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cca.2025.120817_bb0065","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120817_bb0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2015.192","article-title":"A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies","volume":"30","author":"Stein","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pathol.2016.03.002","article-title":"Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms","volume":"48","author":"Andrici","year":"2016","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.cca.2025.120817_bb0080","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ijlh.13242","article-title":"Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing","volume":"42","author":"Rahman","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2025.120817_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/10245332.2018.1502944","article-title":"A triplex probe-based TaqMan qPCR assay for Calreticulin type I and II mutation detection","volume":"24","author":"Tang","year":"2019","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.cca.2025.120817_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40291-015-0162-3","article-title":"Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR","volume":"19","author":"Zinke","year":"2015","journal-title":"Mol. Diagn. Ther."},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","article-title":"Immunosuppression by mutated Calreticulin released from malignant cells","volume":"77","author":"Liu","year":"2020","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.cca.2025.120817_bb0100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.2022016846","article-title":"Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms","volume":"141","author":"Pecquet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cca.2025.120817_bb0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-014-0048-6","article-title":"The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Wu","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2025.120817_bb0110","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.7150\/thno.39341","article-title":"Copy number amplification of DNA damage repair pathways potentiates therapeutic resistance in Cancer","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.cca.2025.120817_bb0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cca.2025.120817_bb0120","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/1471-2105-9-514","article-title":"ElliPro: a new structure-based tool for the prediction of antibody epitopes","volume":"9","author":"Ponomarenko","year":"2008","journal-title":"BMC Bioinformatics"},{"issue":"23","key":"10.1016\/j.cca.2025.120817_bb0125","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann. Lab. Med."},{"issue":"7","key":"10.1016\/j.cca.2025.120817_bb0135","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.V99.7.2612","article-title":"Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis","volume":"99","author":"Viallard","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.cca.2025.120817_bb0140","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6\u00b7soluble IL-6 receptor (sIL-6R), and IL-6\u00b7sIL-6R\u00b7sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2025.120817_bb0145","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.2147\/CMAR.S316919","article-title":"Alterations of signaling pathways in essential Thrombocythemia with Calreticulin mutation","volume":"13","author":"Hui","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"10","key":"10.1016\/j.cca.2025.120817_bb0150","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2025.120817_bb0155","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1158\/1078-0432.CCR-18-3777","article-title":"Unfolding the role of Calreticulin in myeloproliferative neoplasm pathogenesis","volume":"25","author":"Merlinsky","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cca.2025.120817_bb0160","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-023-37277-3","article-title":"Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation","volume":"14","author":"Papadopoulos","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cca.2025.120817_bb0165","doi-asserted-by":"crossref","first-page":"19838","DOI":"10.1038\/s41598-019-56236-x","article-title":"CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms","volume":"9","author":"Belcic Mikic","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0170","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152904","article-title":"Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody","volume":"23","author":"Tvorogov","year":"2022","journal-title":"EMBO Rep."},{"issue":"19","key":"10.1016\/j.cca.2025.120817_bb0175","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.cca.2025.120817_bb0180","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.cca.2025.120817_bb0185","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2025.120817_bb0190","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1172\/JCI70408","article-title":"Pegylated IFN-\u03b1 regulates hepatic gene expression through transient Jak\/STAT activation","volume":"124","author":"Dill","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.cca.2025.120817_bb0195","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:29:20Z","timestamp":1773948560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125006965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0009898125006965"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120817","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of plasma mutant calreticulin for diagnosis and therapeutic response assessment of peginterferon-\u03b1 in myeloproliferative neoplasms: A proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120817"}}